Brown and White Ventures podcast host, and fund co-founder Jim Aroune, welcomes Anthony Saleh, Ph..D., CEO of the BWV-backed company miRecule.

miRecule is a biotechnology company focused on developing RNA therapeutics for diseases that lack existing treatments or cannot be addressed by traditional small molecule or biologic drugs.

RNA acts as an intermediary molecule that reads genetic information from DNA to create proteins.By intervening in this information flow, miRecule aims to correct mutations or repress inappropriate gene expression that causes diseases.

The company currently focuses on rare, severe muscle diseases, including Facioscapulohumeral muscular dystrophy (FSHD) and centronuclear myopathy (CNM)

Saleh’s interest in healthcare and science began as an undergraduate student at St. Bonaventure University (2001), where he studied biology and biochemistry. His commitment to this field became personal after learning that FSHD, a disease he is working to treat, runs in his own family.

Saleh conducted research at Johns Hopkins University and the National Institutes of Health before moving into the private sector.

miRecule's FSHD program has been licensed to pharmaceutical partner Sinofi. It is preparing for human clinical trials.